Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

37
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
37
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

871
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
871
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

434
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
434
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

817
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
817

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Hepatic SMARCA4 predicts HCC recurrence and promotes tumour cell proliferation by regulating SMAD6 expression.

Cell death & disease·2018
Same author

Determination of phthalate esters in soil using a quick, easy, cheap, effective, rugged, and safe method followed by GC-MS.

Journal of separation science·2018
Same author

PRDM14 is expressed in germ cell tumors with constitutive overexpression altering human germline differentiation and proliferation.

Stem cell research·2018
Same author

Downregulation of gasdermin D promotes gastric cancer proliferation by regulating cell cycle-related proteins.

Journal of digestive diseases·2018
Same author

An Artificial Flexible Visual Memory System Based on an UV-Motivated Memristor.

Advanced materials (Deerfield Beach, Fla.)·2018
Same author

Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice.

Journal of hepatology·2017

Video Experimental Relacionado

Updated: Sep 9, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.4K

Efectos de la inhibición del receptor de angiotensina-neprilisina en el metabolismo energético miocárdico y

Caiming Cheng1,2,3, Yu Nie1,4, Di Chen1,3

  • 1Department of Cardiology, Affiliated Zhongshan Hospital of Dalian University, Dalian, China.

Frontiers in cardiovascular medicine
|August 28, 2025
PubMed
Resumen

El inhibidor del receptor de angiotensina-neprilisina (ARNI) redujo significativamente el gasto energético miocárdico (EME) en pacientes con infarto agudo de miocardio (AMI) y insuficiencia cardíaca (HF). Los niveles más altos de MEE predijeron la muerte cardíaca y el aumento del riesgo de mortalidad.

Palabras clave:
ARNI (en inglés)El MEEInfarto agudo del miocardiometabolismo energéticoinsuficiencia cardíaca

Más Videos Relacionados

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

8.6K
A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

5.0K

Videos de Experimentos Relacionados

Last Updated: Sep 9, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.4K
Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

8.6K
A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

5.0K

Área de la Ciencia:

  • Cardiología
  • Medicina metabólica

Sus antecedentes:

  • El infarto agudo de miocardio (AMI) complicado por insuficiencia cardíaca (HF) presenta desafíos significativos en el tratamiento del paciente.
  • La comprensión del metabolismo energético miocárdico es crucial para mejorar las evaluaciones de pronóstico en estos pacientes.

Objetivo del estudio:

  • Evaluar el impacto del inhibidor de los receptores de angiotensina-neprilisina (ARNI) en el metabolismo energético miocárdico (MEE) en pacientes con IAM e HF.
  • Evaluar la relación entre la MEE y el pronóstico a largo plazo en esta cohorte de pacientes.

Principales métodos:

  • Análisis retrospectivo de 210 pacientes con IAM complicado por HF, seguidos durante 1 año.
  • Los pacientes se dividieron en grupos ARNI y no ARNI (ACEI/ ARB).
  • Los principales resultados incluyeron cambios en el MEE y en los indicadores de pronóstico.

Principales resultados:

  • El ARNI redujo significativamente el MEE en comparación con el ACEI/ARB (P < 0,01).
  • Se observó una MEE más alta en el grupo HFrEF en comparación con HFmrEF (P < 0,05).
  • El grupo ARNI tuvo tasas más bajas de IH, infarto de miocardio recurrente y deterioro de la función renal.
  • Un límite MEE de 178 kcal/ min predijo la muerte cardíaca (AUC=0,74, P=0,007) y se asoció con un aumento de la mortalidad por todas las causas.

Conclusiones:

  • ARNI reduce efectivamente el MEE en pacientes con IAM y IH.
  • MEE es un predictor significativo del pronóstico, correlacionado con la disfunción sistólica del ventrículo izquierdo y el riesgo de mortalidad.
  • Un valor de MEE superior a 178 kcal/min indica un mayor riesgo de muerte cardíaca y de mortalidad general.